613 related articles for article (PubMed ID: 34526102)
1. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Qian W; Zhao M; Wang R; Li H
J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
Front Immunol; 2021; 12():785091. PubMed ID: 35111155
[TBL] [Abstract][Full Text] [Related]
3. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
[TBL] [Abstract][Full Text] [Related]
4. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
5. Development of a nanobody-based immunoassay for the sensitive detection of fibrinogen-like protein 1.
Zhang WT; Liu TT; Wu M; Chen XC; Han L; Shi ZZ; Li YY; Li XY; Xu HX; Gong LK; Xu PH; Geng Y
Acta Pharmacol Sin; 2021 Nov; 42(11):1921-1929. PubMed ID: 33633363
[TBL] [Abstract][Full Text] [Related]
6. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
7. Implication of the hepatokine, fibrinogen-like protein 1 in liver diseases, metabolic disorders and cancer: The need to harness its full potential.
Liu XH; Qi LW; Alolga RN; Liu Q
Int J Biol Sci; 2022; 18(1):292-300. PubMed ID: 34975333
[TBL] [Abstract][Full Text] [Related]
8. Research Progress Concerning Dual Blockade of Lymphocyte-Activation Gene 3 and Programmed Death-1/Programmed Death-1 Ligand-1 Blockade in Cancer Immunotherapy: Preclinical and Clinical Evidence of This Potentially More Effective Immunotherapy Strategy.
Qi Y; Chen L; Liu Q; Kong X; Fang Y; Wang J
Front Immunol; 2020; 11():563258. PubMed ID: 33488573
[TBL] [Abstract][Full Text] [Related]
9. FGL1 in plasma extracellular vesicles is correlated with clinical stage of lung adenocarcinoma and anti-PD-L1 response.
Zhang Y; Zhang K; Wen H; Ge D; Gu J; Zhang C
Clin Exp Immunol; 2024 Mar; 216(1):68-79. PubMed ID: 38146642
[TBL] [Abstract][Full Text] [Related]
10. Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Wang Z; Wu X
Cancer Med; 2020 Nov; 9(21):8086-8121. PubMed ID: 32875727
[TBL] [Abstract][Full Text] [Related]
11. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
Mariuzza RA; Shahid S; Karade SS
J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
[TBL] [Abstract][Full Text] [Related]
12. Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy.
Qian Y; Sun Y; Shi P; Zhou X; Zhang Q; Dong Q; Jin S; Qiu L; Niu X; Zhou X; Zhao W; Wu Y; Zhai W; Gao Y
Acta Pharm Sin B; 2024 Mar; 14(3):1150-1165. PubMed ID: 38486998
[TBL] [Abstract][Full Text] [Related]
13. Targeting fibrinogen-like protein 1 enhances immunotherapy in hepatocellular carcinoma.
Lin M; He J; Zhang X; Sun X; Dong W; Zhang R; Xu Y; Lv L
J Clin Invest; 2023 May; 133(9):. PubMed ID: 37115693
[TBL] [Abstract][Full Text] [Related]
14. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
[TBL] [Abstract][Full Text] [Related]
15. The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm.
Lecocq Q; Keyaerts M; Devoogdt N; Breckpot K
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374804
[TBL] [Abstract][Full Text] [Related]
16. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
[TBL] [Abstract][Full Text] [Related]
17. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors.
Yan Y; Zhang L; Zuo Y; Qian H; Liu C
Arch Immunol Ther Exp (Warsz); 2020 Nov; 68(6):36. PubMed ID: 33185750
[TBL] [Abstract][Full Text] [Related]
19. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
[TBL] [Abstract][Full Text] [Related]
20. A Double-Antibody Sandwich ELISA for Sensitive and Specific Detection of Swine Fibrinogen-Like Protein 1.
Zhang X; Zhu H; Zheng X; Jiao Y; Ning L; Zhou EM; Mu Y
Front Immunol; 2021; 12():670626. PubMed ID: 33968077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
